Health science solutions provider Revvity Inc (NYSE: RVTY) announced on Monday that it has entered a strategic collaboration with life science company Element Biosciences Inc to commercialise an in vitro diagnostic (IVD) workflow for neonatal sequencing.

This partnership builds on Revvity's introduction of an automated next-generation sequencing (NGS) workflow for newborn research and supports Element's progress toward regulatory approval of its AVITI sequencing system.

The collaboration will co-develop a comprehensive IVD solution for newborn sequencing, while providing immediate access to a research-use-only (RUO) version of the workflow. The IVD solution will enhance both Element's AVITI sequencing system and Revvity's sequencing workflow, which includes sample collection devices, nucleic acid extractors, NGS preparation kits and software for data analysis.

Revvity, with over USD2.7bn in revenue for 2023, serves customers across pharmaceutical, biotech, diagnostic labs, academia and governments.

Element Biosciences focuses on providing affordable, high-quality sequencing tools for research markets.